دورية أكاديمية

Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study.

التفاصيل البيبلوغرافية
العنوان: Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study.
المؤلفون: Swisher, Elizabeth M., Aghajanian, Carol, O'Malley, David M., Fleming, Gini F., Kaufmann, Scott H., Levine, Douglas A., Birrer, Michael J., Moore, Kathleen N., Spirtos, Nick M., Shahin, Mark S., Reid, Thomas J., Friedlander, Michael, Steffensen, Karina Dahl, Okamoto, Aikou, Sehgal, Vasudha, Ansell, Peter J., Dinh, Minh H., Bookman, Michael A., Coleman, Robert L.
المصدر: Obstetrical & Gynecological Survey; May2022, Vol. 77 Issue 5, p277-278, 2p
قاعدة البيانات: Complementary Index
الوصف
تدمد:00297828
DOI:10.1097/01.ogx.0000827620.82650.68